Form 4: CFO Glenn Worman Acquires 100,000 DMII Shares

Drugs Made In America Acquisition II Corp. CFO Glenn Worman acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Summary

• Glenn C. Worman, the Chief Financial Officer (CFO) of Drugs Made In America Acquisition II Corp. (DMII), acquired 100,000 ordinary shares.
• The transaction occurred on September 26, 2025.
• The shares were acquired from Drugs Made In America Acquisition II LLC, which is the Issuer's sponsor.
• The acquisition was made for no consideration, meaning the shares were received without payment.
• Following this transaction, Glenn C. Worman beneficially owns 100,000 ordinary shares directly.

Sentiment

Score: 7

Explanation: The acquisition of 100,000 ordinary shares by the CFO, even for no consideration, increases insider ownership and aligns management's interests with shareholders, signaling confidence in the company's future.

Positives

• Increased insider ownership by the CFO, aligning management's interests with those of shareholders.
• The acquisition of shares for no consideration represents a significant personal benefit to the CFO.

Negatives

• The shares were acquired for no consideration, which differs from an open market purchase and does not represent a direct cash investment by the CFO.

Industry Context

This transaction reflects an increase in insider ownership within a Special Purpose Acquisition Company (SPAC) structure. Insider acquisitions, even for no consideration, are often viewed as a positive signal of management's confidence in the company's future prospects, particularly as the SPAC approaches or completes a de-SPAC transaction.

Related Party Transactions

• Glenn C. Worman, CFO, acquired 100,000 ordinary shares from Drugs Made In America Acquisition II LLC, the Issuer's sponsor. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's commitment and belief in the company's long-term value.
• Employees might perceive this as a sign of stability and confidence from leadership.

Key Dates

Recommendation

The increase in insider ownership by the CFO is a positive signal, indicating management's alignment with shareholder interests. However, as the shares were acquired for no consideration rather than an open market purchase, it warrants a 'hold' rather than a 'buy' recommendation until further operational or financial updates are available to assess the company's fundamental value.

Keywords

Drugs Made In America Acquisition II Corp, DMII, Glenn Worman, CFO, Insider Trading, Form 4, Share Acquisition, Beneficial Ownership, SPAC